64Cu-SarTate Drug Asset Due Diligence Report 2026

This 64Cu-SarTate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether 64Cu-SarTate can convert its Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals profile and SSTR2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	64Cu-SarTate (query alias: 64Cu-SarTate)
Modality / target	Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals; SSTR2; SSTR2 antagonists
Highest global status	Phase 2
Originator	University of Melbourne, Clarity Pharmaceuticals Ltd.
Active developers	Clarity Pharmaceuticals Ltd.

The MCP disease footprint includes Gastro-Enteropancreatic Neuroendocrine Tumor. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04440956	Early Phase 1	Completed	10	Primary endpoint not disclosed in English source
NCT04438304	Phase 2	Completed	45	Primary endpoint not disclosed in English source
NCT04023331	Phase 1/2	Terminated	21	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

DISCO update: Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.

Phase 2; n=45; evaluation: Positive. Reported fields: AE = 7.0 Pts ; Lesion detection rate = 44.4 % ( 32.3 - 57.5)

Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors with focus on foci-to-liver uptake ratio findings

Phase 2; n=45; evaluation: Positive. Reported fields: Sensitivity(for discordant foci) = 94.7 % ; Sensitivity(for discordant foci) = 5.4 %

DISCO: Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors with focus on liver findings.

Phase 2; n=45; evaluation: Positive. Reported fields: AE(SARTATE-related) = 9.0 Pts ; Number of foci(liver) = 180.0 Foci

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

64Cu-SarTate addresses Gastro-Enteropancreatic Neuroendocrine Tumor. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 21 matched transaction record(s) under the scope “target-level comparable: SSTR2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SSTR2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-06	Vertex to Acquire Crinetics Pharmaceuticals	Approved	US$1,000.0M stated total
2025-12-11	Everest Medicines Announces Commercialization Service Agreement with Hasten	Approved	Financial terms not disclosed
2025-09-26	Orsini Selected as Specialty Pharmacy Partner for Crinetics’ PALSONIFY™ (paltusotine)	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Formulations for radiotherapy and diagnostic imaging”. The milestone feed surfaced a patent-application signal described as “Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO